Skip to main content
. 2007 Sep 25;5:38. doi: 10.1186/1477-7827-5-38

Table 1.

PCR primers, cycling conditions and positive controls used.

Primer Sens Primer Antisense Primer Size (bp)* annealing (celsius) cycles extension positive control
Keratin 1 5'-gatgaaggccacggtgatca-3' 5'-gacttgagttggggtgccta-3' 627 64 36 1 min KLE
Keratin 4 5'-ctccagcaaaaaccttgagc-3' 5'-aagtcattctcggctgctgt-3' 186 58 36 30 sec KLE
Keratin 5 5'-tctcgccagtcaagtgtgtc-3' 5'-atagccacccactccacaag-3' 247 58 36 30 sec KLE
Keratin 7 5'-caggatgtggtggaggactt-3' 5'-ttgctcatgtaggcagcatc-3' 116 58 30 30 sec KLE
Keratin 8 5'-agatgaaccggaacatcagc-3' 5'-tccagcagcttcctgtaggt-3' 262 58 30 30 sec KLE
Keratin 13 5'-gtcttcagcacccagaggag-3' 5'-ttgcagaaaggcaggaaact-3' 246 58 36 30 sec Hec-1-A
Keratin 18 5'-cacagtctgctgaggttgga-3' 5'-gagctgctccatctgtaggg-3' 164 58 36 30 sec KLE
Keratin 19 5'-tttgagacggaacaggctct-3' 5'-gccatgacctcatattggct-3' 275 58 30 30 sec KLE
Keratin 20 5'-acgccagaacaacgaatacc-3' 5'-acgaccttgccatccactac-3' 198 61 36 30 sec KLE
Vimentin 5'-gagaactttgccgttgaagc-3' 5'-tccagcagcttcctgtaggt-3' 170 58 36 30 sec KLE
Desmin 5'-caagctgcaggaggagattc-3' 5'-ggcagtgaggtctggcttag-3' 241 62 36 30 sec KLE
ER alpha 5'-gtgcctggctagagatcctg-3' 5'-agagacttcagggtgctgga-3' 265 66 36 30 sec MCF-7
ER beta 5'-tcaggcatgcgagtaacaag-3' 5'-gcttttactgtcctctgccg-3' 167 65 36 30 sec MCF-7
PR-A 5'-gcttcaagttagccaagaagagt-3' 5'-ctggaaattcaacactcagtg-3' 290 58 36 30 sec Ishikawa
PR-B 5'-acaccttgcctgaagtttcg-3' 5'-tccaagacactgtccagcag-3' 160 64 35 30 sec Ishikawa
MMP-2 5'-aggcaagtggtccgtgtgaa-3' 5'-acagtggacatggcggtctcag-3' 369 66 36 30 sec KLE
MMP-9 5'-caacatcacctattggatcc-3' 5'-cgggtgtagagtctctcgct-3' 479 60 36 30 sec KLE
MMP-14 5'-ccagggtctcaaatggcaaca-3' 5'-ccatggaagccctcggcaaa-3' 219 66 36 30 sec **
TIMP-1 5'-accagaccaccttataccagcg-3' 5'-ggactggaagcccttttcagag-3' 395 58 36 30 sec RL-95-2
TIMP-2 5'-atgcagatgtagtgatcagggc-3' 5'-gatgaagtcacagagggtgatg-3' 272 58 36 30 sec RL-95-2
β-actin 5'-gaggatcttcatgaggtagtctgtcaggtc-3' 5'-caactgggacgacatggagaagatctggca-3' 348 58 25 30 sec none

* Size of amplified fragment; ** PMA-treated THP-1 cells